Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2020-06-08 Regulatory Filings
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Correction Directorate Change & Audited accounts
Regulatory Filings Classification · 1% confidence The document starts with an 'RNS Number' and is explicitly identified as an amendment to a previous announcement released under RNS. The content details a Directorate Change (appointment of Dr. Suzanne Dilly as CEO) and an extension for the publication of audited accounts. The primary focus is on management changes and regulatory compliance updates related to reporting deadlines. Since it announces changes in senior management (Directorate Change), the most specific category is Board/Management Information (MANG). Although it mentions audited accounts extension, the core news is the board change. It is not a full 10-K, AR, or ER, but a specific announcement about management structure. The RNS header suggests it is a regulatory filing, but MANG is more specific for the content.
2020-06-08 English
Directorate Change & Audited accounts extension
Regulatory Filings Classification · 1% confidence The document is clearly identified as an RNS Number announcement from the London Stock Exchange. The content announces two main items: 1) A Directorate Change (appointment of Dr Suzanne Dilly as CEO) and 2) An Extension of the reporting deadline for audited accounts. The Directorate Change directly maps to the 'Board/Management Information' (MANG) category. Since the document contains significant management/director information and is a formal regulatory announcement (RNS), MANG is the most specific fit for the primary content. Although it mentions an extension for the annual report, it is not the report itself, nor is it solely a general regulatory filing (RNS) given the specific nature of the director appointment details provided.
2020-06-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number : 6765O' and contains a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. Although it is distributed via RNS (Regulatory Filings), the specific content dictates the classification should be 'MRQ' (Major Shareholding Notification). The document details the date the threshold was crossed (29/05/2020) and the resulting total positions (9.07%).
2020-06-02 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1368 characters) and begins with 'RNS Number : 6632O', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Second Price Monitoring Extension' for a security, which is a procedural market announcement related to trading halts or volatility controls. This type of general, non-specific regulatory update that doesn't fit into the defined categories (like ER, 10-K, DIV, etc.) is best classified under the general regulatory fallback category, RNS (Regulatory Filings).
2020-06-02 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1351 characters) and begins with an 'RNS Number', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for a security, which is a routine operational update related to trading mechanisms, not a comprehensive financial report (like 10-K or IR) or a specific corporate action like a dividend or management change. Since it is a general regulatory announcement that doesn't fit the highly specific categories (like DIV, MANG, 10-K, ER), the most appropriate classification is the general regulatory filing fallback category.
2020-06-02 English
Collaboration Agreement Signed
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 6521O' and is clearly formatted as a regulatory news service announcement from the London Stock Exchange (LSE). It announces a specific corporate event: signing a collaboration agreement regarding VAL201 for COVID-19 treatment. The text explicitly states, 'This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.' and concludes with information about RNS being the news service of the LSE. This structure strongly indicates a general regulatory announcement that doesn't fit the more specific categories like 10-K, ER, or DIV. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements.
2020-06-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.